Dialyzer membrane and the type of heparin used can influence lipid parameters. However, there are limited and debatable data concerning lipid alterations during a single hemodialysis session. Moreover, the role of hemoconcentration after every hemodialysis session confuses the real effect of the heparin on lipid profile. We investigated the acute effect of heparin administration on lipids in hemodialysis patients, but on an off-hemodialysis day in order to eliminate any effect of ultrafiltration. We studied six patients on hemodialysis, six patients on peritoneal dialysis, and six healthy persons. The study was performed in two phases (1 week apart). In phase A, we used unfractionated heparin (5000 IU, intravenous), whereas in phase B, low-molecular-weight heparin (3500 anti-FXa, intravenous) was used. Total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and Lp(a) were estimated before and 1, 2, 3, and 4 hours after heparin administration. We observed a reduction only in triglycerides (at the first, second, and third hour) in both phases in all groups. The other lipid parameters were not affected. In conclusion, acute administration of both types of heparin seems to affect only triglyceride levels in patients on renal replacement therapy. ASAIO Journal 2007; 53:46-49.
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Dyslipidemia is a common metabolic disorder in patients on hemodialysis and contributes to the high incidence of atherosclerosis observed in this population. 1,2 Previous long-term studies have shown that the type of dialyzer membrane 3 and the type of heparin 4 used might influence serum lipid parameters. However, there are limited and debatable data concerning the lipid changes observed during a single hemodialysis session. [5] [6] [7] In a recent study, we showed that the type of heparin and membrane used do not seem to affect serum lipid levels during a single hemodialysis procedure, and that the observed changes in lipid parameters are mainly due to hemoconcentration. 8 We undertook the present study to investigate the acute effects of unfractionated and low-molecular-weight heparin administration on serum lipids in hemodialysis patients on an off-hemodialysis day in order to eliminate any effect of the dialyzer membrane type and hemoconcentration.
Patients and Methods

Patients
Six patients (group 1) undergoing chronic hemodialysis were included in the study. Six patients (group 2) on peritoneal dialysis (PD) program and six healthy subjects (group 3) were used as the control groups. Patients and healthy individuals were in stable condition for the last 6 months. The demographic characteristics (age, sex, smoking habit, body weight) were similar between groups ( Table 1) . Moreover, the duration of hemodialysis and PD and the primary renal disease were similar among the chronic kidney disease patients.
None of the patients was receiving drugs affecting lipids metabolism. Exclusion criteria were bleeding tendency (clinical evidences, aPTT Ͼ 40 seconds before heparin administration), diabetes mellitus, hypothyroidism, infections, systemic disorders or other diseases, and drugs affecting lipids metabolism.
Ethics Issues
The study was approved by the hospital ethics boards and all patients provided informed consent. The principal investigators (K.P.K., E.K., and K.C.S.) were responsible for collecting the data during the trial and for submitting the manuscript.
Method
The study was performed in two phases (1 week apart). In phase A, we used unfractionated heparin (UFH, Leo Pharmaceutical Products, Ballerup, Denmark) in an intravenous dose of 5000 IU, whereas in phase B, a low-molecular-weight heparin (LMWH, Leo Pharmaceutical Products) in an intravenous dose of 3500 anti-FXa was administered. In group 1, the study was performed in an off-hemodialysis day (the day between the second and third hemodialysis session of the week), whereas in PD patients the PD schedule had been stopped 16 hours before (18:00 on the former day).
Blood samples were taken after an overnight fast (12 hours) for the determination of serum lipid parameters [total cholesterol (T-chol), triglycerides (TRG), high-density lipoprotein cholesterol (HDL-chol), low-density lipoprotein cholesterol (LDL-chol), and Lp(a)] immediately before (t 0 ) and 1 (t 1 ), 2 (t 2 ), 3 (t 3 ), and 4 (t 4 ) hours after the heparin administration.
Serum was isolated by centrifugation at 1500g for 15 min and was stored at 4°C until analysis. Serum samples for Lp(a) measurement were stored at -80°C until analysis. Concentra- tions of T-chol and TRG were determined enzymatically on an Olympus AU600 Clinical Chemistry analyzer (Olympus Diagnostica, Hamburg, Germany). Our laboratory is currently participating in the Murex Clinical Chemistry Quality Assessment Programme. The coefficient of variation values in this program, in the past 2 years ranged between 0.99% and 2.14% for cholesterol, and between 1.73% and 3.36% for TRG. HDLchol was determined by a direct assay (Olympus Diagnostica). Lp(a) was quantified by an enzyme immunoassay (sandwich-ELISA assay, Macra Lp(a), Temuro Medical Corporation Diagnostic Division, Elktron, MD). LDL-chol was calculated using the Friedewald formula. 9 No food or fluid was permitted during the 4-hour duration of the study.
Statistical Analysis
The laboratory parameters were expressed as mean Ϯ SD. Because of the skewed distribution of Lp(a), the concentrations were expressed as median.
Statistical analysis was performed by analysis of variance (ANOVA) for repeated measurements, except for Lp(a) values where the Friedman ANOVA was used. Furthermore analysis of covariance was performed taking into account the baseline values of measured parameters as a covariate. Statistical significance was accepted at p Ͻ 0.05.
Results
According to our findings, there were significant changes only in serum TRG levels in all three groups tested for both types of heparin used ( Table 2 ). The influence of heparin (UFH and LMWH) was observed starting 1 hour from administration and was high for approximately 3 to 4 hours. Moreover, UFH type had a greater and longer action on TRG than did LMWH.
No other alterations in lipid parameters were observed in either phase of the study in any of the three groups ( Table 3) .
Discussion
In this study, we investigated the acute influence of heparins (UFH and LMWH) on lipid parameters in patients on renal replacement therapy on an off-hemodialysis day. The influence of heparins on patients with chronic kidney disease was compared with the influence of both types of heparin in a group of PD patients and in a group of healthy subjects.
In all groups, a significant decrease in serum TRG was noted; the lower concentration of serum TRG was observed during the first 3 hours after heparin administration.
Our results are in agreement with two recent studies, in which both types of heparin had been used in healthy subjects. 10, 11 In these studies, there was a peak of LPL activity and a reduction in serum TRG values during the first hour after heparin administration. Thereafter, LPL activity decreased toward a plateau, whereas TRG increased (after 2-3 hours) to baseline values. Similar are the results of our previously published study in which we observed a reduction of serum TRG in the first hour of hemodialysis. 8 It is well known that infusion of heparin (UFH or LMWH) releases endothelial-bound lipoprotein lipase (LPL), the major enzyme responsible for hydrolyzing TRG in circulating li- poproteins. However, LMWH may release endothelial-bound LPL less efficiently and thereby produce less derangement of lipid metabolism compared with UFH, 12,13 although a recent study indicates that LMWH disturbs the LPL system as much or more than UFH. 14 It has been reported that reduction in LPLactivity is influenced by other mechanisms: a) LPL has a rather short lifetime at the endothelium, 15, 16 and b) the enzyme is slowly washed away by blood and extracted by the liver, where it is degraded. 17, 18 The effect of heparin, via LPL, on serum TRG during the hemodialysis session exists for the first 2 or 3 hours, and it is similar to that observed in healthy subjects. Except for the short lifetime at the endothelium and the hepatic degradation of LPL, a circulating nondialyzable LPL inhibitor 19, 20 and the increased production of cytokines (IL-2, IL-6, IL-8, TNF-␣) 21, 22 -especially IL-6, which reduces the levels of LPL 23 -may play some role in the reduction of LPL activity during dialysis. Although the effects of heparin (UFH, LMWH) persist 3 hours after its administration (half-life: 1 hour for UFH and 3 hours for LMWH), 24 the influence of heparin on LPL levels may be overridden by the previously mentioned mechanisms. Therefore, although heparin has a transient influence on TRG during the hemodialysis session, at the end of the session the values of lipid parameters remain almost unchanged. 14, 25 According to our previous study, the increase that we observed was due to hemoconcentration. 8 The absence of the dialysis procedure in the present study emphasizes the hypertriglyceridemic action of both heparins used over the 3-hour period. 8, 12, 14 However, with long-term use of LMWH instead of UFH, the possibly less efficient release of LPL could lead to a lesser exhaustion of LPL stores and might positively influence serum lipid parameters in a dialysis population. 26, 27 Various forms of LMWH preparations are different in many aspects, and their influence on lipid metabolism could be as heterogeneous as the substances themselves. 28 However, because in this study we used only one form of LMWH, we cannot comment on the above statement.
In conclusion, both types of heparin used seem to affect only TRG both in renal replacement therapy patients on an offhemodialysis day and in healthy subjects.
